Poolbeg Pharma to present at investor conferences

Poolbeg Pharma

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, today announced that members of its management team will be attending four upcoming investor events across September and October.

· Proactive Investors One2One Forum (virtual) on 16 Sep 2021. Registration Link: click here

· Small Company Champion Investor Presentation on 17 Sep 2021 at The Menphys Hub, Bassett Street South, Wigston, Leicester LE18 4PE. Registration Link: click here

· Shares Magazine Investor Webinar (virtual) on 5 Oct 2021. Registration link will be available on the Poolbeg Pharma website: click here

· London South East Webinar (virtual) on 19 Oct 2021. Registration link will be available on the Poolbeg Pharma website: click here

The above event details may be subject to change. Further information and any updates will be on the events section of the Poolbeg Pharma website.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma , said:

“Following continuing demand after an oversubscribed AIM listing in July and a share price above the IPO price, I am looking forward to sharing how our capital light model and a scalable platform for growth will deliver value creation for our shareholders. Poolbeg Pharma is targeting a rapidly expanding market of infectious diseases, which is expected to exceed $250B by 2025. These events will be an opportunity to discuss our attractive, Phase II ready lead asset (POLB 001) tackling the inflammatory response to severe influenza, and our special access to a unique data bank of 20 years of infectious disease data in humans which we will mine to identify new, compelling therapeutics.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs.

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs.

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy.

Poolbeg Pharma targets severe flu and cytokine storms

Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy.

POLB 001 targets deadly cytokine storms in cancer therapy

Cytokine Release Syndrome (CRS) complicates cancer immunotherapy, but Poolbeg Pharma’s POLB 001 offers a groundbreaking oral solution to enhance patient outcomes.

Search

Search